Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...
UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback